Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN W KIM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1003886698
CMS profile
319
Location
FULLERTON, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,611.57

89 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,611.57 89

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN W KIM

NPI 1003886698 · CMS profile ID 319

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

FULLERTON, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003886698?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN W KIM, NPI 1003886698, CMS profile ID 319. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003886698?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). STEVEN W KIM, NPI 1003886698, CMS profile ID 319. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003886698?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
STEVEN W KIM, NPI 1003886698, CMS profile ID 319, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–89 of 89 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1003886698?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

89 matching records · $1,611.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 89 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–89 of 89.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $30.3206/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055432501 CMS
Novartis Pharmaceuticals Corporation $34.7706/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992120885 CMS
Gilead Sciences, Inc. $16.3506/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025951453 CMS
Celgene Corporation $24.4905/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015384415 CMS
PFIZER INC. $17.9605/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050550169 CMS
Amgen Inc. $13.5905/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020151251 CMS
Pharmacyclics LLC, An AbbVie Company $23.7505/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998288683 CMS
Pharmacyclics LLC, An AbbVie Company $0.9405/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998288685 CMS
Celgene Corporation $2.9405/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015384407 CMS
Celgene Corporation $5.6905/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015384423 CMS
BeiGene USA, Inc. $18.7305/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051179465 CMS
ARRAY BIOPHARMA INC $22.3905/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049120859 CMS
Incyte Corporation $27.9605/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044492339 CMS
Celgene Corporation $15.2404/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015384335 CMS
Merck Sharp & Dohme LLC $25.1304/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048558943 CMS
Pharmacyclics LLC, An AbbVie Company $0.9204/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998288677 CMS
Pharmacyclics LLC, An AbbVie Company $23.3304/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998288679 CMS
Pharmacyclics LLC, An AbbVie Company $0.4904/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998288681 CMS
Amgen Inc. $18.0904/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020151247 CMS
E.R. Squibb & Sons, L.L.C. $14.7104/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015384327 CMS
AstraZeneca Pharmaceuticals LP $24.4804/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015905725 CMS
Celgene Corporation $23.5103/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015384303 CMS
Merck Sharp & Dohme LLC $19.0603/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048558941 CMS
Celgene Corporation $0.2103/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015384311 CMS
Celgene Corporation $18.3003/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015384319 CMS
Puma Biotechnology, Inc. $28.6602/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059049811 CMS
Celgene Corporation $13.2702/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015384197 CMS
Celgene Corporation $12.4002/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015384205 CMS
Pharmacyclics LLC, An AbbVie Company $25.0902/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998288675 CMS
Pharmacyclics LLC, An AbbVie Company $0.5902/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998288673 CMS
Celgene Corporation $22.8802/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015384187 CMS
Celgene Corporation $20.9402/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015384147 CMS
E.R. Squibb & Sons, L.L.C. $13.4201/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015384221 CMS
Eisai Inc. $22.3301/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023333893 CMS
Celgene Corporation $25.2101/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015384099 CMS
Astellas Pharma US Inc $15.3601/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033868413 CMS
Pharmacyclics LLC, An AbbVie Company $22.3501/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998288669 CMS
Pharmacyclics LLC, An AbbVie Company $0.8501/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998288671 CMS
Celgene Corporation $22.5901/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015384107 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $596.10 30
PY2020 $410.90 15
PY2021 $507.54 25
PY2022 $1,137.41 57
PY2023 $1,611.57 89
PY2024 $1,522.52 80
PY2025 $2,484.08 111

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $169,718.38 37
PY2024 Principal investigator $261,906.95 23
PY2023 Principal investigator $269,906.81 31
PY2022 Principal investigator $237,789.37 17
PY2021 Principal investigator $40,704.27 9
PY2020 Principal investigator $55,589.58 13
PY2019 Principal investigator $37,421.22 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $396.00 12/18/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202531260
Principal investigator 1 Incyte Corporation $263.25 12/16/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240578630
Principal investigator 1 Incyte Corporation $15,179.69 11/25/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240578624
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,965.00 11/24/2025 Non-covered Recipient Entity
SAINT JUDE HERITAGE FULLERTON MEDICAL PLAZA
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190304573
Principal investigator 1 ABBVIE INC. $612.00 11/20/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202525040
Principal investigator 1 Incyte Corporation $16,745.12 11/10/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240578618
Principal investigator 1 ABBVIE INC. $360.00 10/16/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202517311
Principal investigator 1 ABBVIE INC. $504.00 09/18/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202511396
Principal investigator 1 Merck Sharp & Dohme LLC $7,940.00 09/18/2025 Non-covered Recipient Entity
Providence Medical Foundation
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232926767
Principal investigator 1 Organon Llc $6,940.00 09/18/2025 Non-covered Recipient Entity
Providence Medical Foundation
3475-587 No dispute reported 06/30/2026 1173042428
Principal investigator 1 ABBVIE INC. $6,000.00 09/16/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202511008
Principal investigator 1 ABBVIE INC. $3,326.00 09/03/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202507477
Principal investigator 1 ABBVIE INC. $7,600.00 09/02/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202506935
Principal investigator 1 ABBVIE INC. $468.00 08/22/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202505637
Principal investigator 1 ABBVIE INC. $540.00 07/23/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202499356
Principal investigator 1 ABBVIE INC. $28,852.65 07/09/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202497622
Principal investigator 1 ABBVIE INC. $468.00 06/20/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202492587
Principal investigator 1 ABBVIE INC. $4,100.00 06/05/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202490471
Principal investigator 1 ABBVIE INC. $253.50 06/05/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202490473
Principal investigator 1 ABBVIE INC. $550.00 05/13/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202484705
Principal investigator 1 ABBVIE INC. $432.00 04/23/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202478627
Principal investigator 1 ABBVIE INC. $750.00 04/17/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202477504
Principal investigator 1 Incyte Corporation $968.99 04/15/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240578612
Principal investigator 1 ABBVIE INC. $550.00 04/09/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202475159
Principal investigator 1 ABBVIE INC. $1,368.00 03/20/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
M22-574 - Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202465031
Principal investigator 1 ABBVIE INC. $6,282.90 03/07/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
M16-191 - Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202460336
Principal investigator 1 ABBVIE INC. $559.00 03/06/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
M16-191 - Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202457143
Principal investigator 1 ABBVIE INC. $1,609.40 02/05/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
M16-191 - Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202445364
Principal investigator 1 Incyte Corporation $2,628.25 01/30/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240578606
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,292.00 01/23/2025 Non-covered Recipient Entity
SAINT JUDE HERITAGE FULLERTON MEDICAL PLAZA
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190304575
Principal investigator 1 ABBVIE INC. $825.00 01/16/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
M16-191 - Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202439420
Principal investigator 1 Incyte Corporation $28,778.03 01/14/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240578604
Principal investigator 1 ABBVIE INC. $564.20 01/09/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
M16-191 - Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202437679
Principal investigator 1 ABBVIE INC. $2,000.00 01/09/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
M16-191 - Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202437683
Principal investigator 1 ABBVIE INC. $1,200.00 01/09/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
M16-191 - Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202437703
Principal investigator 1 ABBVIE INC. $550.00 01/02/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
M16-191 - Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202435268
Principal investigator 1 ABBVIE INC. $1,297.40 01/02/2025 Non-covered Recipient Entity
PROVIDENCE MEDICAL FOUNDATION
M16-191 - Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis No dispute reported 06/30/2026 1202435272